Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023
July 13, 2023 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response
June 26, 2023 06:30 ET
|
Agios Pharmaceuticals, Inc.
– Study’s Primary Efficacy Endpoint Achieved, with 46.2% of Patients in the 50 mg BID Mitapivat Arm and 50.0% of Patients in the 100 mg BID Mitapivat Arm Achieving a Hemoglobin Response, Compared to...
Agios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023
June 05, 2023 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Appoints Catherine Owen to Board of Directors
May 25, 2023 07:00 ET
|
Agios Pharmaceuticals, Inc.
– John Maraganore Completes Tenure on Agios Board After Nearly a Dozen Years of Service – – Kaye Foster to Be Appointed Lead Independent Director – CAMBRIDGE, Mass., May 25, 2023 (GLOBE...
Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress
May 11, 2023 10:00 ET
|
Agios Pharmaceuticals, Inc.
– Agios to Present New Analyses from ACTIVATE, ACTIVATE-T and Long-Term Extension Studies in Adults with PK Deficiency Reinforcing Clinical Benefit of PYRUKYND® (mitapivat) on Hemoglobin, Hemolysis,...
Agios Reports Business Highlights and First Quarter 2023 Financial Results
May 04, 2023 07:00 ET
|
Agios Pharmaceuticals, Inc.
– On Track for PYRUKYND® (mitapivat) Data Readouts of the Phase 2 Portion of the RISE UP Study in Sickle Cell Disease in Mid-2023 and the Phase 3 ENERGIZE and ENERGIZE-T Studies in Thalassemia in 2024...
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023
April 25, 2023 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Appoints Jeffrey Capello to Board of Directors
April 19, 2023 07:00 ET
|
Agios Pharmaceuticals, Inc.
– Board Member Paul Clancy Will Step Down at the End of His Term – CAMBRIDGE, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular...
Agios to Webcast Conference Call of First Quarter 2023 Financial Results on May 4, 2023
April 13, 2023 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Publishes 2023 Environmental, Social and Governance (ESG) Report
April 03, 2023 07:00 ET
|
Agios Pharmaceuticals, Inc.
– Report Highlights Continued Progress on Patient Access, Health Equity, Diversity and Flexibility – – Aligns with the Sustainability Accounting Standards Board (SASB) Standards for the...